Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.
Roxane Laboratories told a Federal Circuit panel Tuesday that Vanda Pharmaceuticals' dosage method patent for its antipsychotic Fanapt is "quintessential conventional activity," in its effort to overturn a Delaware court's finding...To view the full article, register now.
Already a subscriber? Click here to view full article